Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

02 Feb 26

Updated

20 Aug 26

Views

Not Invested

Shared on 20 Aug 26

Fair value Increased 97%

EOLS: Index Inclusion And Injectables Expansion Will Support Bullish Multiyear Outlook

Evolus lifts its outlook and expands its lineup of injectable treatments through a new U.S. partnership, aiming to widen its reach beyond its current products. It also lands in a major industry index, which could put the company on more investors’ radars as it pushes toward its longer-term goals.

0 views

Shared on 06 Aug 26

Fair value Decreased 39%

EOLS: Index Addition And New Aesthetic Products Will Shape Balanced Outlook

Evolus lands new partnerships and product launches that could broaden its injectable lineup, including a skin-quality treatment for the US and a fresh filler range rolling out in Europe. At the same time, a key market estimate moves lower, raising the question of whether these additions can translate into stronger long-term results.

0 views

Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains

EOLS: Index Inclusion And Injectables Expansion Will Support Bullish Multiyear Outlook

EOLS: Index Addition And New Aesthetic Products Will Shape Balanced Outlook

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Evolus

Company analysis

CEO & management